Skip to main content
Erschienen in: European Journal of Medical Research 1/2023

Open Access 01.12.2023 | Research

Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients

verfasst von: Dechao Feng, Jie Wang, Xu Shi, Dengxiong Li, Wuran Wei, Ping Han

Erschienen in: European Journal of Medical Research | Ausgabe 1/2023

Abstract

Background

Prostate cancer (PCa) is usually considered as cold tumor. Malignancy is associated with cell mechanic changes that contribute to extensive cell deformation required for metastatic dissemination. Thus, we established stiff and soft tumor subtypes for PCa patients from perspective of membrane tension.

Methods

Nonnegative matrix factorization algorithm was used to identify molecular subtypes. We completed analyses using software R 3.6.3 and its suitable packages.

Results

We constructed stiff and soft tumor subtypes using eight membrane tension-related genes through lasso regression and nonnegative matrix factorization analyses. We found that patients in stiff subtype were more prone to biochemical recurrence than those in soft subtype (HR 16.18; p < 0.001), which was externally validated in other three cohorts. The top ten mutation genes between stiff and soft subtypes were DNAH, NYNRIN, PTCHD4, WNK1, ARFGEF1, HRAS, ARHGEF2, MYOM1, ITGB6 and CPS1. E2F targets, base excision repair and notch signaling pathway were highly enriched in stiff subtype. Stiff subtype had significantly higher TMB and T cells follicular helper levels than soft subtype, as well as CTLA4, CD276, CD47 and TNFRSF25.

Conclusions

From the perspective of cell membrane tension, we found that stiff and soft tumor subtypes were closely associated with BCR-free survival for PCa patients, which might be important for the future research in the field of PCa.
Hinweise
Dechao Feng and Jie Wang contributed equally to this work

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Many human cancers are closely related to age, especially for urinary tumors [14]. Prostate cancer (PCa) is one of the most frequent malignancies in men, which harbors great prevalence in aging males [1, 5, 6]. This phenomenon is exacerbating as the global population ages and the disease burden of this disease is predicted to be increased [1, 5, 711]. Standard therapies for clinically localized PCa mainly contain radical prostatectomy (RP) and radical radiotherapy (RT) [5, 1214]. Unfortunately, a considerable number of patients will develop biochemical recurrence (BCR) despite radical treatments [15]. BCR means the return of measurable PSA, which is associated with high possibility of clinical recurrence, leading to the elevated risks of metastasis and death [6, 13, 14, 1619]. Currently, the recommended management method for BCR by European Association of Urology is mainly based on prostate-specific antigen doubling time (PSA-DT), Gleason score, International Society of Urological Pathology (ISUP) grade and interval from primary therapy to biochemical failure [15], but there are still defects in the process of clinical application. With the advent of next-generation sequencing, more and more biomarkers for the management of BCR based on transcriptomic data are identified from different perspectives [8, 12, 14, 2022]. Interestingly, radiomics attracts clinicians’ attention in PCa, such as prostate volume and other traits [23, 24]. However, investigators have not yet considered BCR in PCa from the perspective of membrane tension.
Membrane tension is not a new concept, which refers to the force per unit length acting on a cross-section of membrane, regulating many vital biological processes [25]. Over the past decades, the important role of cell and tissue mechanics in tumorigenesis, progression and metastasis was gradually recognized [2629]. The decreasing membrane tension of tumor cells is associated with increasing invasion and metastatic capacity, which is proved to be mediated by the Bin/Amphiphysin/Rvs (BAR) family proteins [30]. In contrast, in normal epithelial cells, the underlying mechanism for the homeostatic maintenance of the higher plasma membrane tension is achieved through the membrane-to-cortical attachment regulated by the ezrin, radixin, and moesin (ERM) proteins. If this homeostasis is disrupted, epithelial cells may transform into mesenchymal migratory phenotype powered by BAR proteins, leading to greater capacity for invasion and metastasis [30, 31]. In addition, tumor cells can also feel the changes in exogenous forces through a complex series of cellular sensing and signaling pathway conduction mechanisms, which can affect and regulate the cellular metabolic processes, and then promote the tumor proliferation and progression [28, 3234]. Therefore, to better reveal the role and mechanism of membrane tension in the progress of tumorigenesis, progression, and metastasis in PCa, we divided PCa patients into 2 subtypes and proposed the concepts of stiff tumor and soft tumor based on 8 identified membrane tension-related genes and the cancer genome atlas (TCGA) database, which provided new perspective and insights for the management of the prognosis and survival of PCa patients.

Methods

Data preparation and identification of molecular subtypes

The workflow of our study is illustrated in Fig. 1. We downloaded the gene matrix and clinical data of PCa patients in the TCGA database as the training set from our previous study [20]. For the validation set, we used 2 gene expression omnibus (GEO) datasets (GSE46602 [35], GSE116918 [36]) and MSKCC2010 [37] (http://​www.​cbioportal.​org/​). Moreover, we obtained total 44 membrane-related genes from previously published literature [38]. Subsequently, we performed differential analysis between tumor tissue and normal tissue within the TCGA cohort based on R package “limma”. Deferentially expressed genes (DEGs) were defined as llogFCl ≥ 0.4 and p.adj. < 0.05. After the intersection of DEGs and membrane-related genes, we used Lasso regression to identify the final genes. Based these genes, we used nonnegative matrix factorization (NMF) method to divide the patients in TCGA cohorts into two subtypes. We set the cluster number of K index from 2 to 10 and determined the average contour width of the common member matrix using the R package “NMF”. Three external cohorts were used to validate the prognostic value of TCGA subtypes, including GSE46602 [35], GSE116918 [36] and MSKCC2010 [37]. The clinical features between these two subtypes were analyzed.

Mutation landscape and gene set enrichment analysis (GSEA)

We downloaded RNA-sequencing profiles, genetic mutation and corresponding clinical information of PCa patients from TCGA database (https://​portal.​gdc.​com). The data of mutations were obtained and visualized based on R package “maftools”. We also conducted the differences analysis of mutation frequency between these two subtypes. When performing GSEA analysis by GSEA software (version 3.0) (http://​www.​gsea-msigdb.​org), [39] several gene set databases were used including: “c2.cp.kegg.v7.4.symbols.gmt” and “h.all.v7.4.symbols.gmt” from the molecular signatures database [39, 40]. The minimum gene set was defined as 5 and the maximum gene set was 5000. Resampling was performed as 1000 times. P value < 0.05 and false discovery rate < 0.05 were considered statistically significant.

Tumor stemness, tumor heterogeneity and tumor immune microenvironment (TIME) analysis

For tumor stemness indexes, we compared differentially methylated probes-based stemness scores (DMPss), DNA methylation-based stemness scores (DNAss), enhancer elements/DNA methylation-based stemness scores (ENHss), epigenetically regulated DNA methylation-based stemness scores (EREG-METHss), epigenetically regulated RNA expression-based stemness scores (EREG.EXPss), RNA expression-based stemness scores (RNAss) [41] and mRNAsi [42] algorithms between two subtypes. For tumor heterogeneity, we compared homologous recombination deficiency (HRD), loss of heterozygosity (LOH), neoantigen (NEO), tumor ploidy, tumor purity, mutant-allele tumor heterogeneity (MATH), tumor mutation burden (TMB) and microsatellite instability (MSI) [43, 44] between two subtypes. All these data could be obtained from our previous study [9]. In addition, for the TIME analysis, we used Cibersortx and ESTIMATE algorithms [4547] to assess the overall tumor microenvironment and immune components and compared the differences of tumor microenvironment scores and 54 immune checkpoints between these two subtype. Moreover, we calculated the Tumor Immune Dysfunction and Exclusion (TIDE) score to predict potential response of immune checkpoint blockade (ICB) therapy [48] and compared the differences between these two subtypes. All the comparison of differences between these two subtypes were based on the Wilcokson rank sum test.

Statistical analysis

All analyses were completed through software R 3.6.3 and its suitable packages. For abnormal distribution, we used Wilcoxon test to compare differences between groups. Survival analysis was conducted through log-rank test and presented as Kaplan–Meier curve. Statistical significance was set as two-sided p < 0.05. Significant marks were as follows: not significance (ns), p ≥ 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Results

The identification of “stiff tumor” and “soft tumor”

The PCa expression profile in the TCGA database included 498 tumor samples and 52 normal samples. The DEGs between tumor samples and normal samples were detected using R package “limma” and finally 4895 genes were obtained to analyze (Fig. 2A). Then, after the intersection of DEGs and membrane-related genes, 16 candidate genes were obtained (Fig. 2A). Through Lasso regression, when lambda (λ) equaled 4.7 \({e}^{-3}\), we obtained the optimal model (Fig. 2B) and 8 identified genes, including FNBP1, PICK1, FGFR1, MSN, TIMP1, BAIAP2, EGF and FLNA (Fig. 2C). Based on these 8 membrane-mediated genes, using NMF algorithm, we divided 430 PCa patients in TCGA cohort into 2 subtypes and named them “stiff tumor” and “soft tumor” based on their biological meanings (Fig. 2D). Similar results were observed in MSKCC2010, GSE116918 and GSE46602 cohorts (Fig. 2E-G). We found the BCR risk of “stiff tumor” was significantly higher than “soft tumor” (HR = 16.18; Fig. 2H). The baseline comparison showed balanced clinical features between “stiff tumor” and “soft tumor” (Table 1). Similar prognostic results were observed in MSKCC2010, GSE116918 and GSE46602 cohorts (Fig. 2I-K). For the differences of mutation landscape between “stiff tumor” and “soft tumor”, the top ten genes were DNAH9, NYNRIN, PTCHD4, WNK1, ARFGEF1, HRAS, ARHGEF2, MYOM1, ITGB6 and CPS1 (Fig. 3A).
Table 1
The clinical features between TCGA stiff and soft tumor subtypes for prostate cancer patients
Characteristic
Soft tumor
Stiff tumor
P value
Samples
354
76
 
Age, median (IQR)
61 (56, 66)
62 (57, 66)
0.526
Gleason score, n (%)
  
0.297
 6
32 (7.4%)
7 (1.6%)
 
 7
175 (40.7%)
31 (7.2%)
 
 8
50 (11.6%)
9 (2.1%)
 
 9
97 (22.6%)
29 (6.7%)
 
T stage, n (%)
  
1.000
 T2
128 (30.2%)
27 (6.4%)
 
 T3
214 (50.5%)
47 (11.1%)
 
 T4
7 (1.7%)
1 (0.2%)
 
Race, n (%)
  
0.317
 Asian
9 (2.2%)
2 (0.5%)
 
 Black or African American
45 (10.8%)
5 (1.2%)
 
 White
288 (69.2%)
67 (16.1%)
 
N stage, n (%)
  
1.000
 N0
251 (66.9%)
55 (14.7%)
 
 N1
57 (15.2%)
12 (3.2%)
 
Residual tumor, n (%)
  
0.465
 No
228 (54.4%)
45 (10.7%)
 
 Yes
117 (27.9%)
29 (6.9%)
 
IQR interquartile range

Functional enrichment analysis, TME evaluation and tumor heterogeneity and stemness

For GSEA, protein secretion was highly enriched in “soft tumor” (Fig. 3B) and E2F targets, base excision repair and notch signaling pathway were highly enriched in “stiff tumor” (Fig. 3B-C). For tumor heterogeneity between “stiff tumor” and “soft tumor”, we found TMB in “stiff tumor” was higher than “soft tumor” with statistical significance (Fig. 3D). In terms of immune checkpoints, the expressions of CTLA4, CD276, CD47 and TNFRSF25 were significantly higher in “stiff tumor” (Fig. 3E). In addition, T cells follicular helper were significantly higher in “stiff tumor” than in “soft tumor” (Fig. 3E).

Discussion

The metastasis of malignant cells is usually accompanied by alternation of cell mechanical properties. A line of evidence has shown that tumor cells can promote metastasis and change cell metabolism by reducing membrane tension [28, 30, 3234]. However, PCa appears to deviate from the cell-softening trends described in other cancer models, in which with the increasing of stiffness of PCa cells, the metastasis potential is also increasing [4953]. In addition, a recent study found that the cell and tissue mechanic characteristics of different metastatic potential cells were diverse, which meant the relationship between the metastatic ability and membrane tension and tissue stiffness of PCa cells was not necessarily linear [54]. These confounding results indicate that microenvironment mechanics are a significant yet nuanced factor in the progression of PCa. Based on these facts and by means of analyzing published sequencing data, we identified 8 membrane-related genes (FNBP1, PICK1, FGFR1, MSN, TIMP1, BAIAP2, EGF and FLNA) and used NMF algorithm to divide PCa patients in TCGA cohort into two subtypes based on these genes.
In PCa, there are many reports on FGFR1, TIMP1, and EGF. For instance, FGFR1 is a kind of fibroblast growth factor (FGF)/FGF receptor, which was overexpressed in PCa [55, 56]. Enhanced FGF signaling plays an important role in tumor progression and drug resistance, which can induce angiogenesis, epithelial-to-mesenchymal transition (EMT), and upregulation of AR [5759]. In addition, a recent study indicated that TIMP1 was a significant molecular switch that could determine the effects of senescence in PCa [60]. TIMP1 belongs to the TIMP gene family and encodes natural inhibitors of the matrix metalloproteinases (MMPs), which involves in degradation of the extracellular matrix (ECM) [61]. The degradation of ECM plays a wide range of physiological function in angiogenesis, cell repair and remodeling of tissues, while the deficiency of TIMP1 will break the balance between TIMP and MMPs, resulting in the abnormity of angiogenesis, cell proliferation, and apoptosis [61, 62]. In PCa, the loss of TIMP1 can change the senescence-associated secretory phenotype (SASP) of senescent tumor cells through activation of MMPs, thus promoting tumor metastasis [60]. Moreover, EGF is a significant regulatory factor that can induce EMT through increasing expression of transcription factors responsible for reducing E-cadherin and promoting cancer invasion [63]. In summary, the function and role of these three genes in PCa are relatively established. There are a few reports on FNBP1, PICK1, MSN, BAIAP2, and FLNA in PCa. FNBP1(formin-binding protein 1/17) is an actin skeleton-related protein, which is a member of F-Bar/EFC family. Several researches showed that FNBP1 could affect tumor migration and invasion through affecting the formation of filopodia in bladder cancer [64] and breast cancer cells [65]. In addition, a recent study found the loss of FNBP1 could result in the loss of invasive ability in gastric cancer [66]. Remarkably, a pan-cancer analysis based on bioinformatics found that except the metastatic cancer, low expression of FNBP1 was associated with worse prognosis in breast cancer and lung adenocarcinoma, while high expression of FNBP1 was related to the poor prognosis in stomach adenocarcinoma [67]. These studies showed the expression patterns of FNBP1 were associated with the type of tumor and FNBP1 played an important yet complex role of in cancer invasion and metastasis. For PICK1, current understanding of its role in tumor is still limited. PICK1 was reported to involve in regulating the cell to cell junction in epithelial cells, which was associated with tumor invasion and metastasis [68]. In PCa, Dai et al. found the overexpression of PICK1 could suppress the migration and invasion in vitro and bone metastasis in vivo [69]. MSN encodes moesin protein, which belongs to ERM family and appears to function as link protein between plasma membranes and actin-based cytoskeletons [70]. Additionally, Moesin plays a key role in the control of cell morphology, adhesion, and motility [7072]. The abnormalities of moesin, such as mislocalization, have been proved to be associated with tumor progression in multiple types of tumor [7274]. Furthermore, moesin plays an important role in the EMT process of breast cancer cells and pancreatic cancer cells, and is currently shown to serve as a potential EMT marker for breast cancer and pancreatic cancer [7577]. These results presented the huge potential for MSN in cancer research. BAIAP2 and FLNA are rarely reported in cancer. BAIAP2 is also called IRSp53. A bioinformatic study constructed a prognostic model in esophagus squamous cell carcinoma including BAIAP2 [78]. In addition, Funato et al. [79] found IRSp53 could bind to EPs8 to form a complex, thus enhancing the invasive ability of cancer cells. For FLNA, a study reported that FLNA could directly regulate the metastasis and EMT of chemoresistance colorectal cancer cells [80]. Another study found that in bladder cancer, hexavalent chromium could regulate the expression of FLNA to mediate EMT to promote the proliferation and migration and inhibit the apoptosis of bladder cancer cells. In summary, a series of evidence suggests that the 8 identified genes are associated with tumor metastasis and invasion. Based on the evidences and unique biological functions and meanings of these genes, we named the subtype with bad prognosis as “stiff tumor” and the subtype with relatively good prognosis as “soft tumor”.
We found “stiff tumor” had a much worse prognosis than “soft tumor” and speculated it is associated with the differences in enriched pathways between the two subtypes. E2F targets, base excision repair and notch signaling pathway were highly enriched in “stiff tumor” while protein secretion was highly enriched in “soft tumor”. The enrichment of E2F targets in “stiff tumor” means “stiff tumor” cells may have stronger ability of proliferation, because E2F is the key transcription factor for regulating of cell cycle. It is well known that the disorder of cell cycle is one of the important features of cancer cells [81]. Shorter cell cycle implies a faster proliferation rate, correlating with bad prognosis. In addition, a series of evidence suggests the increased expression of base excision repair related genes was associated with rapid recurrence, metastatic dissemination, and decreased patient survival in PCa [8285], which is consistent with our results. Moreover, a study showed natamycin which was an inhibitor of key BER enzymes DNA polymerase β and DNA Ligase I could significantly inhibit the proliferation of PCa cells in the androgen depleted environment, which furthermore proved that BER signaling pathway played an important role in the bad prognosis in “stiff tumor” [83]. Importantly, we also observed notch signaling pathway enriched in “stiff tumor”. In the physiological state, notch signaling pathway has important role in regulating proliferation, differentiation, cell-fate determination and self-renewal of stem and progenitor cell [8688]. In the pathological state, the deregulation of notch signaling pathway has been demonstrated in a variety of tumors containing PCa and is associated with tumorigenesis and progression [8993]. These results strongly support our findings. Interestingly, we found protein secretion was mainly enriched in “soft tumor”. We speculated this may be due to the upregulation of androgen signaling. A study reported compared with hormone-naïve metastatic PCa, hormone-refractory metastatic PCa showed a decrease of androgen signaling and protein biosynthesis [94]. Therefore, we speculated that the higher level of androgen signaling was associated with higher level of protein synthesis and lower malignancy of PCa cells, which was consistent with better prognosis of “soft tumor”.
For tumor heterogeneity, we observed TMB in “stiff tumor” was higher than “soft tumor”. TMB refers to the total number of mutations present in a single tumor specimen, which can be used to reflect immunogenic neoantigens [95]. In many kinds of tumors, higher TMB means tumor cells carry more tumor antigens, which therefore are more vulnerable to be killed by activated immune cells [95, 96]. In PCa, there was a study showing high level of TMB was significantly associated with poor BCR-free survival [97], which was in agreement with our results. In addition, we compared significant immune checkpoints between “stiff tumor” and “soft tumor” and observed the expression of CTLA4, CD276 and TNFRSF25 was higher in “stiff tumor”, while the expression of CD47 was higher in “soft tumor”. CTLA4 is an important inhibitory receptor mainly expressed on T cells, which plays important role in immunosuppression of tumors [98]. Some studies found high expression of CTLA4 was associated with worse prognosis in different kinds of tumors, including PCa [99102]. CD276 is a newly found molecule in B7 family and probably serves as potential target for multiple kinds of tumors [103]. In PCa, several studies proved that the overexpression of CD276 was associated with bad clinical outcomes in localized PCa [104107]. In addition, another study found that compared with localized cancer, high expression of CD276 was more frequently observed in metastatic cancer and associated with high disease-specific mortality [108]. These results might explain why “stiff tumor” had worse prognosis to some extent.
There is no doubting that intratumor genetic variability causes sampling bias in gene expression profiles. Furthermore, the microenvironment characteristics may differ in different tumor regions, such as the tumor core and invasive margin. More importantly, whether the identified subtypes in this study could be used in clinical practice in a real-world setting still take a long time.

Conclusions

In this study, based on 8 membrane tension-mediated genes and their unique biological function, we obtained “stiff tumor” and “soft tumor” subtypes, which provided references and insights to the potential mechanism of invasion and metastasis in PCa and precision medicine.

Acknowledgements

Not applicable.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2021;71(3):209–49.
2.
3.
Zurück zum Zitat Shih KW, Chen WC, Chang CH, Tai TE, Wu JC, Huang AC, et al. Non-muscular invasive bladder cancer: re-envisioning therapeutic journey from traditional to regenerative interventions. Aging Dis. 2021;12(3):868–85.PubMedPubMedCentralCrossRef Shih KW, Chen WC, Chang CH, Tai TE, Wu JC, Huang AC, et al. Non-muscular invasive bladder cancer: re-envisioning therapeutic journey from traditional to regenerative interventions. Aging Dis. 2021;12(3):868–85.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Feng D, Shi X, You J, Xiong Q, Zhu W, Wei Q, et al. A cellular senescence-related gene prognostic index for biochemical recurrence and drug resistance in patients with prostate cancer. Am J Cancer Res. 2022;12(8):3811–28.PubMedPubMedCentral Feng D, Shi X, You J, Xiong Q, Zhu W, Wei Q, et al. A cellular senescence-related gene prognostic index for biochemical recurrence and drug resistance in patients with prostate cancer. Am J Cancer Res. 2022;12(8):3811–28.PubMedPubMedCentral
7.
Zurück zum Zitat Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.PubMedCrossRef Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Eur Urol. 2017;71(3):437–46.PubMedCrossRef
8.
Zurück zum Zitat Feng D, Li D, Shi X, Xiong Q, Zhang F, Wei Q, et al. A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer. J Transl Med. 2022;20(1):252.PubMedPubMedCentralCrossRef Feng D, Li D, Shi X, Xiong Q, Zhang F, Wei Q, et al. A gene prognostic index from cellular senescence predicting metastasis and radioresistance for prostate cancer. J Transl Med. 2022;20(1):252.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Feng D, Shi X, Zhu W, Zhang F, Li D, Han P, et al. A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. Exp Hematol Oncol. 2022;11(1):55.PubMedPubMedCentralCrossRef Feng D, Shi X, Zhu W, Zhang F, Li D, Han P, et al. A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer. Exp Hematol Oncol. 2022;11(1):55.PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Feng D, Zhang F, Liu L, Xiong Q, Xu H, Wei W, et al. SKA3 serves as a biomarker for poor prognosis in kidney renal papillary cell carcinoma. Int J Gen Med. 2021;14:8591–602.PubMedPubMedCentralCrossRef Feng D, Zhang F, Liu L, Xiong Q, Xu H, Wei W, et al. SKA3 serves as a biomarker for poor prognosis in kidney renal papillary cell carcinoma. Int J Gen Med. 2021;14:8591–602.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Feng D, Zhu W, Shi X, Xiong Q, Li D, Wei W, et al. Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer. Exp Hematol Oncol. 2022;11(1):76.PubMedPubMedCentralCrossRef Feng D, Zhu W, Shi X, Xiong Q, Li D, Wei W, et al. Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer. Exp Hematol Oncol. 2022;11(1):76.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, et al. A ferroptosis-related gene prognostic index associated with biochemical recurrence and radiation resistance for patients with prostate cancer undergoing radical radiotherapy. Front Cell Dev Biol. 2022;10: 803766.PubMedPubMedCentralCrossRef Feng D, Shi X, Xiong Q, Zhang F, Li D, Wei W, et al. A ferroptosis-related gene prognostic index associated with biochemical recurrence and radiation resistance for patients with prostate cancer undergoing radical radiotherapy. Front Cell Dev Biol. 2022;10: 803766.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Mitochondria dysfunction-mediated molecular subtypes and gene prognostic index for prostate cancer patients undergoing radical prostatectomy or radiotherapy. Front Oncol. 2022;12: 858479.PubMedPubMedCentralCrossRef Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Mitochondria dysfunction-mediated molecular subtypes and gene prognostic index for prostate cancer patients undergoing radical prostatectomy or radiotherapy. Front Oncol. 2022;12: 858479.PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Feng D, Xiong Q, Zhang F, Shi X, Xu H, Wei W, et al. Identification of a novel nomogram to predict progression based on the circadian clock and insights into the tumor immune microenvironment in prostate cancer. Front Immunol. 2022;13: 777724.PubMedPubMedCentralCrossRef Feng D, Xiong Q, Zhang F, Shi X, Xu H, Wei W, et al. Identification of a novel nomogram to predict progression based on the circadian clock and insights into the tumor immune microenvironment in prostate cancer. Front Immunol. 2022;13: 777724.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.PubMedCrossRef Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967–87.PubMedCrossRef
16.
Zurück zum Zitat Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol. 2013;10(1):38–48.PubMedCrossRef Roobol MJ, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol. 2013;10(1):38–48.PubMedCrossRef
17.
Zurück zum Zitat Feng D, Shi X, Xiong Q, Zhang F, Li D, Yang L. A gene prognostic index associated with epithelial-mesenchymal transition predicting biochemical recurrence and tumor chemoresistance for prostate cancer. Front Oncol. 2021;11: 805571.PubMedCrossRef Feng D, Shi X, Xiong Q, Zhang F, Li D, Yang L. A gene prognostic index associated with epithelial-mesenchymal transition predicting biochemical recurrence and tumor chemoresistance for prostate cancer. Front Oncol. 2021;11: 805571.PubMedCrossRef
18.
Zurück zum Zitat Feng D, Zhang F, Li D, Shi X, Xiong Q, Wei Q, et al. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer. Immunology. 2022;166(2):197–209.PubMedCrossRef Feng D, Zhang F, Li D, Shi X, Xiong Q, Wei Q, et al. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer. Immunology. 2022;166(2):197–209.PubMedCrossRef
19.
Zurück zum Zitat Feng D, Zhu W, Shi X, Wang Z, Wei W, Wei Q, et al. Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy. Exp Hematol Oncol. 2023;12(1):8.PubMedPubMedCentralCrossRef Feng D, Zhu W, Shi X, Wang Z, Wei W, Wei Q, et al. Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy. Exp Hematol Oncol. 2023;12(1):8.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Energy metabolism-related gene prognostic index predicts biochemical recurrence for patients with prostate cancer undergoing radical prostatectomy. Front Immunol. 2022;13: 839362.PubMedPubMedCentralCrossRef Feng D, Shi X, Zhang F, Xiong Q, Wei Q, Yang L. Energy metabolism-related gene prognostic index predicts biochemical recurrence for patients with prostate cancer undergoing radical prostatectomy. Front Immunol. 2022;13: 839362.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Hu D, Cao Q, Tong M, Ji C, Li Z, Huang W, et al. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer. BMC Med Genomics. 2022;15(1):24.PubMedPubMedCentralCrossRef Hu D, Cao Q, Tong M, Ji C, Li Z, Huang W, et al. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer. BMC Med Genomics. 2022;15(1):24.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Ke Z-B, You Q, Chen J-Y, Sun J-B, Xue Y-T, Zhuang R-B, et al. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients. Comput Biol Med. 2022;2022–07(146): 105711.CrossRef Ke Z-B, You Q, Chen J-Y, Sun J-B, Xue Y-T, Zhuang R-B, et al. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients. Comput Biol Med. 2022;2022–07(146): 105711.CrossRef
23.
Zurück zum Zitat Ferro M, de Cobelli O, Musi G, Del Giudice F, Carrieri G, Busetto GM, et al. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol. 2022;14:17562872221109020.PubMedPubMedCentralCrossRef Ferro M, de Cobelli O, Musi G, Del Giudice F, Carrieri G, Busetto GM, et al. Radiomics in prostate cancer: an up-to-date review. Ther Adv Urol. 2022;14:17562872221109020.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Massanova M, Robertson S, Barone B, Dutto L, Caputo VF, Bhatt JR, et al. The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study. Urol Int. 2021;105(9–10):804–10.PubMedCrossRef Massanova M, Robertson S, Barone B, Dutto L, Caputo VF, Bhatt JR, et al. The comparison of imaging and clinical methods to estimate prostate volume: a single-centre retrospective study. Urol Int. 2021;105(9–10):804–10.PubMedCrossRef
25.
Zurück zum Zitat Pontes B, Monzo P, Gauthier NC. Membrane tension: a challenging but universal physical parameter in cell biology. Semin Cell Dev Biol. 2017;2017–11(71):30–41.CrossRef Pontes B, Monzo P, Gauthier NC. Membrane tension: a challenging but universal physical parameter in cell biology. Semin Cell Dev Biol. 2017;2017–11(71):30–41.CrossRef
26.
Zurück zum Zitat Sung S-Y, Hsieh C-L, Wu D, Chung LWK, Johnstone PAS. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.PubMedCrossRef Sung S-Y, Hsieh C-L, Wu D, Chung LWK, Johnstone PAS. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr Probl Cancer. 2007;31(2):36–100.PubMedCrossRef
27.
Zurück zum Zitat Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571–82.PubMedCrossRef Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63(4):571–82.PubMedCrossRef
28.
Zurück zum Zitat Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, et al. Tumor mechanics and metabolic dysfunction. Free Radical Biol Med. 2015;2015–02(79):269–80.CrossRef Tung JC, Barnes JM, Desai SR, Sistrunk C, Conklin MW, Schedin P, et al. Tumor mechanics and metabolic dysfunction. Free Radical Biol Med. 2015;2015–02(79):269–80.CrossRef
29.
Zurück zum Zitat Castaño Z, Tracy K, McAllister SS. The tumor macroenvironment and systemic regulation of breast cancer progression. Int J Dev Biol. 2011;55(7–9):889–97.PubMedCrossRef Castaño Z, Tracy K, McAllister SS. The tumor macroenvironment and systemic regulation of breast cancer progression. Int J Dev Biol. 2011;55(7–9):889–97.PubMedCrossRef
30.
Zurück zum Zitat Tsujita K, Satow R, Asada S, Nakamura Y, Arnes L, Sako K, et al. Homeostatic membrane tension constrains cancer cell dissemination by counteracting BAR protein assembly. Nat Commun. 2021;12(1):5930.PubMedPubMedCentralCrossRef Tsujita K, Satow R, Asada S, Nakamura Y, Arnes L, Sako K, et al. Homeostatic membrane tension constrains cancer cell dissemination by counteracting BAR protein assembly. Nat Commun. 2021;12(1):5930.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Simunovic M, Evergren E, Callan-Jones A, Bassereau P. Curving cells inside and out: roles of BAR domain proteins in membrane shaping and its cellular implications. Annu Rev Cell Dev Biol. 2019;35:111–29.PubMedCrossRef Simunovic M, Evergren E, Callan-Jones A, Bassereau P. Curving cells inside and out: roles of BAR domain proteins in membrane shaping and its cellular implications. Annu Rev Cell Dev Biol. 2019;35:111–29.PubMedCrossRef
32.
Zurück zum Zitat Park JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, et al. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature. 2020;578(7796):621–6.PubMedPubMedCentralCrossRef Park JS, Burckhardt CJ, Lazcano R, Solis LM, Isogai T, Li L, et al. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature. 2020;578(7796):621–6.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Hamill OP, Martinac B. Molecular basis of mechanotransduction in living cells. Physiol Rev. 2001;81(2):685–740.PubMedCrossRef Hamill OP, Martinac B. Molecular basis of mechanotransduction in living cells. Physiol Rev. 2001;81(2):685–740.PubMedCrossRef
34.
Zurück zum Zitat Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241–54.PubMedCrossRef Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005;8(3):241–54.PubMedCrossRef
35.
Zurück zum Zitat Mortensen MM, Høyer S, Lynnerup A-S, Ørntoft TF, Sørensen KD, Borre M, et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015;5:16018.PubMedPubMedCentralCrossRef Mortensen MM, Høyer S, Lynnerup A-S, Ørntoft TF, Sørensen KD, Borre M, et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015;5:16018.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, et al. Validation of a metastatic assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29(1):215–22.PubMedCrossRef Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, et al. Validation of a metastatic assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29(1):215–22.PubMedCrossRef
37.
Zurück zum Zitat Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
39.
Zurück zum Zitat Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 30. Bioinformatics. 2011;27(12):1739–40.PubMedPubMedCentralCrossRef Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 30. Bioinformatics. 2011;27(12):1739–40.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019;39(1):79.PubMedCrossRef Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond). 2019;39(1):79.PubMedCrossRef
42.
Zurück zum Zitat Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-54 e15.PubMedPubMedCentralCrossRef Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338-54 e15.PubMedPubMedCentralCrossRef
44.
45.
Zurück zum Zitat Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.PubMedPubMedCentralCrossRef Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773–82.PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12: 687975.PubMedPubMedCentralCrossRef Zeng D, Ye Z, Shen R, Yu G, Wu J, Xiong Y, et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front Immunol. 2021;12: 687975.PubMedPubMedCentralCrossRef
47.
Zurück zum Zitat Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.PubMedPubMedCentralCrossRef Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.PubMedPubMedCentralCrossRef
48.
Zurück zum Zitat Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.PubMedPubMedCentralCrossRef Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Bastatas L, Martinez-Marin D, Matthews J, Hashem J, Lee YJ, Sennoune S, et al. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. Biochem Biophys Acta. 2012;1820(7):1111–20.PubMedCrossRef Bastatas L, Martinez-Marin D, Matthews J, Hashem J, Lee YJ, Sennoune S, et al. AFM nano-mechanics and calcium dynamics of prostate cancer cells with distinct metastatic potential. Biochem Biophys Acta. 2012;1820(7):1111–20.PubMedCrossRef
51.
Zurück zum Zitat Lekka M, Gil D, Pogoda K, Dulińska-Litewka J, Jach R, Gostek J, et al. Cancer cell detection in tissue sections using AFM. Arch Biochem Biophys. 2012;518(2):151–6.PubMedCrossRef Lekka M, Gil D, Pogoda K, Dulińska-Litewka J, Jach R, Gostek J, et al. Cancer cell detection in tissue sections using AFM. Arch Biochem Biophys. 2012;518(2):151–6.PubMedCrossRef
53.
Zurück zum Zitat Liu N, Du P, Xiao X, Liu Y, Peng Y, Yang C, et al. Microfluidic-based mechanical phenotyping of androgen-sensitive and non-sensitive prostate cancer cells lines. Micromachines. 2019;10(9):E602.CrossRef Liu N, Du P, Xiao X, Liu Y, Peng Y, Yang C, et al. Microfluidic-based mechanical phenotyping of androgen-sensitive and non-sensitive prostate cancer cells lines. Micromachines. 2019;10(9):E602.CrossRef
54.
Zurück zum Zitat Molter CW, Muszynski EF, Tao Y, Trivedi T, Clouvel A, Ehrlicher AJ. Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Front Cell Devel Biol. 2022;10:932510.CrossRef Molter CW, Muszynski EF, Tao Y, Trivedi T, Clouvel A, Ehrlicher AJ. Prostate cancer cells of increasing metastatic potential exhibit diverse contractile forces, cell stiffness, and motility in a microenvironment stiffness-dependent manner. Front Cell Devel Biol. 2022;10:932510.CrossRef
55.
Zurück zum Zitat Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007;213(1):82–90.PubMedCrossRef Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol. 2007;213(1):82–90.PubMedCrossRef
56.
Zurück zum Zitat Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res: An Official J Am Assoc Cancer Res. 1999;5(5):1063–71. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res: An Official J Am Assoc Cancer Res. 1999;5(5):1063–71.
57.
Zurück zum Zitat Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559–71.PubMedCrossRef Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559–71.PubMedCrossRef
58.
Zurück zum Zitat Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031–41.PubMedPubMedCentralCrossRef Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031–41.PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474-89.e6.PubMedPubMedCentralCrossRef Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32(4):474-89.e6.PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Guccini I, Revandkar A, D’Ambrosio M, Colucci M, Pasquini E, Mosole S, et al. Senescence reprogramming by timp1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021;39(1):68-82.e9.PubMedCrossRef Guccini I, Revandkar A, D’Ambrosio M, Colucci M, Pasquini E, Mosole S, et al. Senescence reprogramming by timp1 deficiency promotes prostate cancer metastasis. Cancer Cell. 2021;39(1):68-82.e9.PubMedCrossRef
61.
Zurück zum Zitat Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):E9739.CrossRef Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, Ramirez-Acuña JM, Perez-Romero BA, Guerrero-Rodriguez JF, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):E9739.CrossRef
62.
Zurück zum Zitat Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38–53.PubMedCrossRef Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38–53.PubMedCrossRef
63.
Zurück zum Zitat Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, et al. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate. 2014;74(5):528–36.PubMedCrossRef Cho KH, Choi MJ, Jeong KJ, Kim JJ, Hwang MH, Shin SC, et al. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate. 2014;74(5):528–36.PubMedCrossRef
64.
Zurück zum Zitat Yamamoto H, Sutoh M, Hatakeyama S, Hashimoto Y, Yoneyama T, Koie T, et al. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J Urol. 2011;185(5):1930–8.PubMedCrossRef Yamamoto H, Sutoh M, Hatakeyama S, Hashimoto Y, Yoneyama T, Koie T, et al. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J Urol. 2011;185(5):1930–8.PubMedCrossRef
65.
Zurück zum Zitat Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol (Northwood, London, England). 2018;35(5):71.CrossRef Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol (Northwood, London, England). 2018;35(5):71.CrossRef
66.
Zurück zum Zitat Yoon BK, Hwang N, Chun K-H, Lee Y, Duarte TPM, Kim J-W, et al. Sp1-induced FNBP1 drives rigorous 3D cell motility in EMT-type gastric cancer cells. Int J Mol Sci. 2021;22(13):6784.PubMedPubMedCentralCrossRef Yoon BK, Hwang N, Chun K-H, Lee Y, Duarte TPM, Kim J-W, et al. Sp1-induced FNBP1 drives rigorous 3D cell motility in EMT-type gastric cancer cells. Int J Mol Sci. 2021;22(13):6784.PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Wang Z, Tian Z, Song X, Zhang J. Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA LUAD and STAD. BMC immunol. 2022;23(1):1.PubMedPubMedCentralCrossRef Wang Z, Tian Z, Song X, Zhang J. Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA LUAD and STAD. BMC immunol. 2022;23(1):1.PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Son J, Park MS, Park I, Lee H-K, Lee S-H, Kang B, et al. Pick1 modulates ephrinB1-induced junctional disassembly through an association with ephrinB1. Biochem Biophys Res Commun. 2014;450(1):659–65.PubMedCrossRef Son J, Park MS, Park I, Lee H-K, Lee S-H, Kang B, et al. Pick1 modulates ephrinB1-induced junctional disassembly through an association with ephrinB1. Biochem Biophys Res Commun. 2014;450(1):659–65.PubMedCrossRef
69.
Zurück zum Zitat Dai Y, Ren D, Yang Q, Cui Y, Guo W, Lai Y, et al. The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone. Br J Cancer. 2017;117(5):685–94.PubMedPubMedCentralCrossRef Dai Y, Ren D, Yang Q, Cui Y, Guo W, Lai Y, et al. The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone. Br J Cancer. 2017;117(5):685–94.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9(1):70–5.PubMedCrossRef Tsukita S, Yonemura S. ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol. 1997;9(1):70–5.PubMedCrossRef
71.
Zurück zum Zitat Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef Bretscher A. Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol. 1999;11(1):109–16.PubMedCrossRef
72.
Zurück zum Zitat Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014;127(Pt 2):267–75.PubMedCrossRef Clucas J, Valderrama F. ERM proteins in cancer progression. J Cell Sci. 2014;127(Pt 2):267–75.PubMedCrossRef
73.
Zurück zum Zitat Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, et al. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2004;10(2):572–80.CrossRef Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, Kurashina K, et al. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res: An Off J Am Assoc Cancer Res. 2004;10(2):572–80.CrossRef
74.
Zurück zum Zitat Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, Samaniego R, et al. Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci. 2009;122(Pt 19):3492–501.PubMedCrossRef
75.
Zurück zum Zitat Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed Abiatari I, Esposito I, Oliveira TD, Felix K, Xin H, Penzel R, et al. Moesin-dependent cytoskeleton remodelling is associated with an anaplastic phenotype of pancreatic cancer. J Cell Mol Med. 2010;14(5):1166–79.PubMed
76.
Zurück zum Zitat Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011;22(24):4750–64.PubMedPubMedCentralCrossRef Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011;22(24):4750–64.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Wang C-C, Liau J-Y, Lu Y-S, Chen J-W, Yao Y-T, Lien H-C. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology. 2012;61(1):78–87.PubMedCrossRef Wang C-C, Liau J-Y, Lu Y-S, Chen J-W, Yao Y-T, Lien H-C. Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition. Histopathology. 2012;61(1):78–87.PubMedCrossRef
78.
Zurück zum Zitat Gao X, Liu Q, Chen X, Chen S, Yang J, Liu Q, et al. Screening of tumor grade-related mRNAs and lncRNAs for esophagus squamous cell carcinoma. J Clin Lab Anal. 2021;35(6):e23797.PubMedPubMedCentralCrossRef Gao X, Liu Q, Chen X, Chen S, Yang J, Liu Q, et al. Screening of tumor grade-related mRNAs and lncRNAs for esophagus squamous cell carcinoma. J Clin Lab Anal. 2021;35(6):e23797.PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Funato Y, Terabayashi T, Suenaga N, Seiki M, Takenawa T, Miki H. IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness. Cancer Res. 2004;64(15):5237–44.PubMedCrossRef Funato Y, Terabayashi T, Suenaga N, Seiki M, Takenawa T, Miki H. IRSp53/Eps8 complex is important for positive regulation of Rac and cancer cell motility/invasiveness. Cancer Res. 2004;64(15):5237–44.PubMedCrossRef
80.
Zurück zum Zitat Cheng M, Jiang Y, Yang H, Zhao D, Li L, Liu X. FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway. Am J Cancer Res. 2020;10(2):403–23.PubMedPubMedCentral Cheng M, Jiang Y, Yang H, Zhao D, Li L, Liu X. FLNA promotes chemoresistance of colorectal cancer through inducing epithelial-mesenchymal transition and smad2 signaling pathway. Am J Cancer Res. 2020;10(2):403–23.PubMedPubMedCentral
81.
82.
Zurück zum Zitat Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, et al. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer. JAMA Oncol. 2016;2(4):471–80.PubMedPubMedCentralCrossRef Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, et al. Patient-level DNA damage and repair pathway profiles and prognosis after prostatectomy for high-risk prostate cancer. JAMA Oncol. 2016;2(4):471–80.PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Vasquez JL, Lai Y, Annamalai T, Jiang Z, Zhang M, Lei R, et al. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020;2020–01(168):241–50.CrossRef Vasquez JL, Lai Y, Annamalai T, Jiang Z, Zhang M, Lei R, et al. Inhibition of base excision repair by natamycin suppresses prostate cancer cell proliferation. Biochimie. 2020;2020–01(168):241–50.CrossRef
84.
Zurück zum Zitat CGAR Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef CGAR Network. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–25.CrossRef
85.
Zurück zum Zitat Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–51.PubMedPubMedCentralCrossRef Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50(5):645–51.PubMedPubMedCentralCrossRef
86.
88.
Zurück zum Zitat Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (New York, NY). 1999;284(5415):770–6.CrossRef Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (New York, NY). 1999;284(5415):770–6.CrossRef
89.
Zurück zum Zitat Kawaguchi K, Kaneko S. Notch signaling and liver cancer. Adv Exp Med Biol. 2021;2021(1287):69–80.CrossRef Kawaguchi K, Kaneko S. Notch signaling and liver cancer. Adv Exp Med Biol. 2021;2021(1287):69–80.CrossRef
90.
Zurück zum Zitat Shen Q, Reedijk M. Notch signaling and the breast cancer microenvironment. Adv Exp Med Biol. 2021;2021(1287):183–200.CrossRef Shen Q, Reedijk M. Notch signaling and the breast cancer microenvironment. Adv Exp Med Biol. 2021;2021(1287):183–200.CrossRef
91.
Zurück zum Zitat Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal cancer. Cells. 2020;9(6):E1549.CrossRef Tyagi A, Sharma AK, Damodaran C. A review on notch signaling and colorectal cancer. Cells. 2020;9(6):E1549.CrossRef
92.
Zurück zum Zitat Wang X-D, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol. 2006;290(1):66–80.PubMedCrossRef Wang X-D, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol. 2006;290(1):66–80.PubMedCrossRef
93.
Zurück zum Zitat Villaronga MA, Bevan CL, Belandia B. Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets. 2008;8(7):566–80.PubMedCrossRef Villaronga MA, Bevan CL, Belandia B. Notch signaling: a potential therapeutic target in prostate cancer. Curr Cancer Drug Targets. 2008;8(7):566–80.PubMedCrossRef
94.
Zurück zum Zitat Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41–51.PubMedCrossRef Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007;39(1):41–51.PubMedCrossRef
95.
Zurück zum Zitat Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol: Official J Eur Soc Med Oncol. 2019;30(1):44–56.CrossRef Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol: Official J Eur Soc Med Oncol. 2019;30(1):44–56.CrossRef
96.
Zurück zum Zitat Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–73.PubMedCrossRef Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–73.PubMedCrossRef
97.
Zurück zum Zitat Luo C, Chen J, Chen L. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Int Immunopharmacol. 2020;2020–09(86): 106709.CrossRef Luo C, Chen J, Chen L. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Int Immunopharmacol. 2020;2020–09(86): 106709.CrossRef
98.
Zurück zum Zitat Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;2020(1248):7–32.CrossRef Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;2020(1248):7–32.CrossRef
99.
Zurück zum Zitat Kern R, Panis C. CTLA-4 expression and its clinical significance in breast cancer. Arch Immunol Et Ther Exp. 2021;69(1):16.CrossRef Kern R, Panis C. CTLA-4 expression and its clinical significance in breast cancer. Arch Immunol Et Ther Exp. 2021;69(1):16.CrossRef
100.
Zurück zum Zitat Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRef Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.PubMedPubMedCentralCrossRef
101.
Zurück zum Zitat Liu J-N, Kong X-S, Huang T, Wang R, Li W, Chen Q-F. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study. Front Immunol. 2020;2020(11):2048.CrossRef Liu J-N, Kong X-S, Huang T, Wang R, Li W, Chen Q-F. Clinical implications of aberrant PD-1 and CTLA4 expression for cancer immunity and prognosis: a pan-cancer study. Front Immunol. 2020;2020(11):2048.CrossRef
102.
Zurück zum Zitat Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–79.PubMedCrossRef Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015;68(2):267–79.PubMedCrossRef
103.
104.
Zurück zum Zitat Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7–H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67(16):7893–900.PubMedCrossRef Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7–H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67(16):7893–900.PubMedCrossRef
105.
Zurück zum Zitat Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7–H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Dis. 2017;20(1):28–35.CrossRef Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, et al. Correlation of B7–H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Dis. 2017;20(1):28–35.CrossRef
106.
Zurück zum Zitat Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol: Official J Japanese Urol Assoc. 2012;19(8):749–56.CrossRef Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, et al. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population? Int J Urol: Official J Japanese Urol Assoc. 2012;19(8):749–56.CrossRef
107.
Zurück zum Zitat Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7–H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104(49):19458–63.PubMedPubMedCentralCrossRef Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7–H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104(49):19458–63.PubMedPubMedCentralCrossRef
108.
Zurück zum Zitat Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, et al. Tumor B7–H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):767–74.PubMedCrossRef Amori G, Sugawara E, Shigematsu Y, Akiya M, Kunieda J, Yuasa T, et al. Tumor B7–H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(3):767–74.PubMedCrossRef
Metadaten
Titel
Membrane tension-mediated stiff and soft tumor subtypes closely associated with prognosis for prostate cancer patients
verfasst von
Dechao Feng
Jie Wang
Xu Shi
Dengxiong Li
Wuran Wei
Ping Han
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
European Journal of Medical Research / Ausgabe 1/2023
Elektronische ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01132-4

Weitere Artikel der Ausgabe 1/2023

European Journal of Medical Research 1/2023 Zur Ausgabe